Recordati SpAMEX:RECN 71 Days Payable is 147.73 as of Mar. 2026, which is 8% above its 10-year median of 136.59. GuruFocus rates MEX:RECN with a GF Score™ of 71/100 and a GF Value™ of MXN1,150.22 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Recordati SpA ranks better than 73.46% on this metric.
The historical rank and industry rank for Recordati SpA's Days Payable or its related term are showing as below:
MEX:RECN'
s Days Payable Range Over the Past 10 Years
Min: 116.91 Med: 136.59 Max: 146.68
Current: 146.68
During the past 13 years, Recordati SpA's highest Days Payable was 146.68. The lowest was 116.91. And the median was 136.59.
MEX:RECN's Days Payable is ranked better than 73.46% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs MEX:RECN: 146.68
Recordati SpA's Days Payable
increased
from Mar. 2025 (129.42) to Mar. 2026 (147.73).
It may suggest that Recordati SpAdelayed paying its suppliers.
Recordati SpA Days Payable Related Terms
Recordati SpA Days Payable Historical Data
* Premium members only.
The historical data trend for Recordati SpA's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RECN vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Days Payable distribution charts can be found below:
* The bar in red indicates where Recordati SpA's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Recordati SpA's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MEX:RECN) has a Days Payable of 147.73 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Recordati SpA and its competitors. This is near median its historical median of 136.59. Over the past decade, Recordati SpA's Days Payable has ranged from 116.91 to 146.68. According to the industry distribution chart, Recordati SpA ranks #245 out of 923 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is Recordati SpA's Days Payable too high?
Recordati SpA's current Days Payable of 147.73 is near median its 10-year median of 136.59. Over the past 10 years, this metric has ranged from a low of 116.91 to a high of 146.68. The Drug Manufacturers industry median Days Payable is 90.98. Recordati SpA's value of 147.73 is 62.4% above this industry median. Based on the distribution chart, Recordati SpA ranks #245 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Recordati SpA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #245 out of 923 companies for Days Payable. This puts Recordati SpA in the upper half of its industry. The industry median Days Payable is 90.98. Recordati SpA's value of 147.73 is 62.4% above this benchmark. Historically, Recordati SpA's own Days Payable has ranged from 116.91 to 146.68 over the past decade. While the company's 10-year median is 136.59 vs. the industry median of 90.98, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current Days Payable of 147.73 is 62.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current Days Payable is 147.73, which is near median its own 10-year median of 136.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MEX:RECN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,150.22, compared to a current price of MXN1,019.79 — trading 11.3% below its estimated fair value. The current Days Payable is 147.73, which is near median its 10-year median of 136.59 and 62.4% above the Drug Manufacturers industry median of 90.98. Recordati SpA's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Recordati SpA (MEX:RECN), the current Days Payable is 147.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MEX:RECN) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of MXN1,019.79 is trading 11.3% below its estimated GF Value™ of MXN1,150.22.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MEX:RECN:
Days Payable: 147.73 (near median its 10-year median of 136.59)
GF Value™: MXN1,150.22 vs. price of MXN1,019.79 (11.3% below fair value)
Industry Position: 62.4% above the Drug Manufacturers median (#245 of 923)
No single metric tells the full story. See the MEX:RECN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
71GF Score
Get the complete analysis for MEX:RECN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RECN has been successfully added to your 
